Erenumab for episodic migraine prophylaxis

References

• Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223–231.
   PubMed Web of Science ®Google Scholar
• Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170(7):1293–1307.
   PubMed Web of Science ®Google Scholar
• Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–552.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge,DN K. Krause. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347(2):478–486.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30(3):272–280.
   PubMed Web of Science ®Google Scholar
• Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia: Int J Headache. 2017. doi: 10.1177/0333102417728873
   Google Scholar
• Eftekhari S, Salvatore CA, Johansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2015;1600:93–109.
   PubMed Web of Science ®Google Scholar
• Messlinger K, Fischer MJ, Lennerz JK. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med. 2011;60(3):82–89.
   PubMedGoogle Scholar
• Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res. 2017;34(9):1784–1795.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Gordan S, Lux A. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 2015;36(6):325–336.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology. 2017;89(12):1237–1243.
   PubMed Web of Science ®Google Scholar
• de Hoon J, van Hecken A, Vandermeulen C, et al. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia: Int J Headache. 2018. doi: 10.1177/0333102418776017
   Google Scholar
• de Hoon J, van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103(5):815–825.
   PubMed Web of Science ®Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382–390.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Devine. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia: Int J Headache. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• Ford JH, Schroeder K, Nyhuis AW, et al. Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm. 2018. doi: 10.18553/jmcp.2018.18058
   Web of Science ®Google Scholar
• Depre C, Antalik L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715–723.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia: Int J Headache. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Buse DC, Lipton RB, Hallstrom Y, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia: Int J Headache. 2018;38(10):1622–1631.
   PubMed Web of Science ®Google Scholar
• McAllister P, Gomez JP, McGill L, et al. Efficacy of erenumab for the treatment of patients with episodic migraine with aura (P4.094). Neurology. 2018;90(15):4.094.
   Google Scholar
• Goadsby PJ, Paemeleire K, Broessner G, et al. Abstracts of the 18th international headache congress. Caphalalgia. 2017;37:13–14. (Efficacy of Erenumab in Subjects with Episodic Migraine with Prior Preventive Treatment Failure(s) (OC-MC-002)).
   Web of Science ®Google Scholar
• Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia: Int J Headache. 2018;38(10):1611–1621.
   PubMed Web of Science ®Google Scholar
• Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1):92.
   PubMedGoogle Scholar
• Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28(7):1002–1011.
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia: Int J Headache. 2007;27(7):814–823.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia: Int J Headache. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia: Int J Headache. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21(7):666–675.
   PubMed Web of Science ®Google Scholar
• Vo P, Wen S, Martel MJ, et al. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia: Int J Headache. 2018. doi: 10.1177/0333102418801579
   Google Scholar
• Engel MA, Becker C, Reeh PW, et al. Role of sensory neurons in colitis: increasing evidence for a neuroimmune link in the gut. Inflamm Bowel Dis. 2011;17(4):1030–1033.
   PubMed Web of Science ®Google Scholar
• Reuter U. A review of monoclonal antibody therapies and other preventative treatments in migraine. Headache. 2018;58(Suppl 1):48–59.
   PubMedGoogle Scholar
• Eller-Smith OC, Nicol AL, Christianson JA. Potential mechanisms underlying centralized pain and emerging therapeutic interventions. Front Cell Neurosci. 2018;12:35.
   PubMed Web of Science ®Google Scholar
• Reinshagen M, Flamig G, Ernst S, et al. Calcitonin gene-related peptide mediates the protective effect of sensory nerves in a model of colonic injury. J Pharmacol Exp Ther. 1998;286(2):657–661.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976–984.
   PubMed Web of Science ®Google Scholar